LU91358I2 - Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium - Google Patents

Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium

Info

Publication number: LU91358I2
Authority: LU; Luxembourg
Prior art keywords: hypertension; diabetic; renal; pharmaceutically acceptable; primary
Prior art date: 1998-07-10

Application number

LU91358C

Other languages

English (en)

Original Assignee

Novartis Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-10

Filing date

2007-09-06

Publication date

2007-11-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91358(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-06 Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag

2007-11-06 Publication of LU91358I2 publication Critical patent/LU91358I2/fr

Links

239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 2
229940127291 Calcium channel antagonist Drugs 0.000 title abstract 2
239000000480 calcium channel blocker Substances 0.000 title abstract 2
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
229960004699 valsartan Drugs 0.000 title abstract 2
230000003276 anti-hypertensive effect Effects 0.000 title 1
206010020772 Hypertension Diseases 0.000 abstract 3
206010012601 diabetes mellitus Diseases 0.000 abstract 3
206010002383 Angina Pectoris Diseases 0.000 abstract 2
206010019280 Heart failures Diseases 0.000 abstract 2
208000001647 Renal Insufficiency Diseases 0.000 abstract 2
201000006370 kidney failure Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
206010003662 Atrial flutter Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
208000007530 Essential hypertension Diseases 0.000 abstract 1
206010018364 Glomerulonephritis Diseases 0.000 abstract 1
206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000003782 Raynaud disease Diseases 0.000 abstract 1
208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
206010039710 Scleroderma Diseases 0.000 abstract 1
206010039808 Secondary aldosteronism Diseases 0.000 abstract 1
206010042600 Supraventricular arrhythmias Diseases 0.000 abstract 1
206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
208000033679 diabetic kidney disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
206010061989 glomerulosclerosis Diseases 0.000 abstract 1
206010020718 hyperplasia Diseases 0.000 abstract 1
206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
201000001474 proteinuria Diseases 0.000 abstract 1
230000002685 pulmonary effect Effects 0.000 abstract 1
208000002815 pulmonary hypertension Diseases 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Fats And Perfumes (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

LU91358C 1998-07-10 2007-09-06 Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium LU91358I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11389398A	1998-07-10	1998-07-10
PCT/EP1999/004842 WO2000002543A2 (fr)	1998-07-10	1999-07-09	Methode de traitement et composition pharmaceutique

Publications (1)

Publication Number	Publication Date
LU91358I2 true LU91358I2 (fr)	2007-11-06

Family

ID=22352165

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU91358C LU91358I2 (fr)	1998-07-10	2007-09-06	Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium
LU92992C LU92992I2 (fr)	1998-07-10	2016-03-07	Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LU92992C LU92992I2 (fr)	1998-07-10	2016-03-07	Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables

Country Status (31)

Country	Link
EP (3)	EP1096932B1 (fr)
JP (1)	JP2002520274A (fr)
KR (2)	KR20040078140A (fr)
CN (2)	CN1234357C (fr)
AT (1)	ATE371448T1 (fr)
AU (1)	AU753486B2 (fr)
BE (1)	BE2016C011I2 (fr)
BR (1)	BR9912021A (fr)
CA (2)	CA2678722C (fr)
CY (4)	CY1107779T1 (fr)
CZ (2)	CZ299429B6 (fr)
DE (2)	DE69936992T2 (fr)
DK (2)	DK2322174T3 (fr)
ES (2)	ES2552639T3 (fr)
FR (1)	FR16C0008I2 (fr)
HU (1)	HU229383B1 (fr)
ID (1)	ID27664A (fr)
IL (3)	IL140665A0 (fr)
LU (2)	LU91358I2 (fr)
NL (2)	NL300290I2 (fr)
NO (2)	NO331802B1 (fr)
NZ (2)	NZ527598A (fr)
PL (1)	PL194604B1 (fr)
PT (2)	PT2322174E (fr)
RU (3)	RU2450813C2 (fr)
SG (1)	SG142116A1 (fr)
SI (2)	SI1096932T1 (fr)
SK (1)	SK285863B6 (fr)
TR (1)	TR200100062T2 (fr)
WO (1)	WO2000002543A2 (fr)
ZA (1)	ZA200100232B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2552639T3 (es)	1998-07-10	2015-12-01	Novartis Pharma Ag	Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
TR200805275T2 (tr) *	1998-12-23	2008-09-22	Novartis Ag	AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
CN1172719C (zh) *	1999-04-28	2004-10-27	武田药品工业株式会社	单纯性视网膜病或前增殖性视网膜病的预防剂、治疗剂、发展抑制剂
EP1197226B1 (fr) *	1999-07-21	2007-11-21	Takeda Pharmaceutical Company Limited	Agents destines a ameliorer les troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
SE9903028D0 (sv) *	1999-08-27	1999-08-27	Astra Ab	New use
BR0013704A (pt)	1999-08-30	2002-05-07	Aventis Pharma Gmbh	Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
AU2001235364A1 (en)	2000-02-25	2001-09-03	Novo-Nordisk A/S	Tetrahydronaphtalene derivatives and their use
WO2001062740A1 (fr) *	2000-02-25	2001-08-30	South Alabama Medical Science Foundation	Analogues de mibefradil et leur utilisation
HUP0301335A3 (en) *	2000-04-12	2006-02-28	Novartis Ag	Combination of organic compounds
DE10018401A1 (de) *	2000-04-13	2001-10-25	Boehringer Ingelheim Pharma	Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
AR033390A1 (es) *	2000-08-22	2003-12-17	Novartis Ag	Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
BR0108823A (pt) *	2000-12-29	2002-12-10	Osmotica Corp	Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
WO2003035046A2 (fr) *	2001-10-18	2003-05-01	Novartis Ag	Composes organiques
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
US20040138306A1 (en)	2002-07-25	2004-07-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE10335027A1 (de) *	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
SE0300988D0 (sv) *	2003-04-03	2003-04-03	Astrazeneca Ab	New use
DK1628663T3 (da)	2003-05-15	2010-03-08	Roskamp Res Llc	Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose
CA2525665A1 (fr) *	2003-05-16	2004-11-25	Novartis Ag	Composition pharmaceutique comportant du valsartan
RU2255740C2 (ru) *	2003-07-02	2005-07-10	Научно-исследовательский институт кардиологии Томского научного центра СО РАМН	Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса
US20050065094A1 (en) *	2003-09-05	2005-03-24	Boehringer Ingelheim International Gmbh	Use of telmisartan for the prevention and treatment of vascular headache
WO2005053687A1 (fr) *	2003-11-25	2005-06-16	Novartis Ag	Combinaison de composes organiques
US20050187262A1 (en) *	2004-01-12	2005-08-25	Grogan Donna R.	Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
CN100364532C (zh) *	2004-09-30	2008-01-30	江苏恒瑞医药股份有限公司	包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
WO2006109164A2 (fr)	2005-04-15	2006-10-19	Research & Innovation Soc. Coop. A R.L.	Methode pour prevenir, retarder ou inverser la progression de pathologies associees a un depot amyloide anormal
GT200600371A (es) *	2005-08-17	2007-03-21		Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0520405D0 (en) *	2005-10-07	2005-11-16	Imp College Innovations Ltd	Biological agents and method
RU2008122712A (ru) *	2005-11-08	2009-12-20	Новартис АГ (CH)	Комбинация органических соединений
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2329805C2 (ru) *	2006-08-28	2008-07-27	Илья Николаевич Медведев	Способ стабилизации эндотелиальной выстилки сосудов у больных метаболическим синдромом
KR100888131B1 (ko) *	2006-10-10	2009-03-11	한올제약주식회사	시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
RU2338527C1 (ru) *	2007-02-26	2008-11-20	Илья Николаевич Медведев	Способ коррекции высокой эндотелиоцитемии у лиц с метаболическим синдромом
JP5411145B2 (ja)	2007-10-05	2014-02-12	アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド	（−）−ニルバジピンエナンチオマーによってアミロイド沈着、アミロイド神経毒性、およびミクログリオーシスを減少させる方法
CN101433536A (zh) *	2007-11-12	2009-05-20	北京瑞康医药技术有限公司	含有烟酸氨氯地平和沙坦类药物的治疗组合物
MX2010007281A (es) *	2007-12-31	2010-10-05	Lupin Ltd	Composiciones farmaceuticas de amlodipina y valsartan.
WO2010006103A1 (fr) *	2008-07-10	2010-01-14	Ore Pharmaceuticals Inc.	Procédé d’amplification de la cognition ou d’inhibition du déclin de la cognition
RU2382644C1 (ru) *	2008-11-05	2010-02-27	Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию"	Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
RU2398581C1 (ru) *	2009-05-28	2010-09-10	Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий)	Способ лечения больных гипертрофической кардиомиопатией
WO2011102702A2 (fr)	2010-02-16	2011-08-25	Krka, D. D., Novo Mesto	Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
IT1400309B1 (it)	2010-05-10	2013-05-24	Menarini Int Operations Lu Sa	Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EA024096B1 (ru) *	2011-04-12	2016-08-31	Борюн Фармасьютикал Ко., Лтд.	Противогипертоническая фармацевтическая композиция
AR089645A1 (es)	2011-08-12	2014-09-10	Boehringer Ingelheim Vetmed	Particula multicapas de sabor enmascarado, metodo, uso, composicion farmaceutica
JPWO2013147137A1 (ja) *	2012-03-30	2015-12-14	味の素株式会社	心不全の治療剤
CZ2013783A3 (cs)	2013-10-08	2015-04-15	Zentiva, K. S	Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
US20180071272A1 (en) *	2014-10-23	2018-03-15	The Trustees Of The University Of Pennsylvania	Novel chronotherapy based on circadian rhythms
RU2616213C2 (ru) *	2015-07-10	2017-04-13	Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России)	Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте
CN108289958A (zh) *	2015-10-31	2018-07-17	Io治疗公司	使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
CN105287550A (zh) *	2015-11-19	2016-02-03	哈尔滨圣吉药业股份有限公司	一种缬沙坦/非洛地平复方制剂及其制备方法
WO2021211944A1 (fr)	2020-04-17	2021-10-21	Honeybrains, Llc	Compositions et méthodes de traitement de troubles neuropsychiatriques
WO2021239106A1 (fr) *	2020-05-28	2021-12-02	杭州起岸生物科技有限公司	Application d'un modificateur de canal potassique sensible à l'atp dans la préparation d'un médicament contre la néphropathie diabétique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4654372A (en) *	1986-01-10	1987-03-31	Warner-Lambert Company	Method for using verapamil for treating stroke
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
PH30484A (en) *	1990-02-19	1997-05-28	Ciba Geigy	Acy compounds pharmaceutical composition containing said compound and method of use thereof
US5492904A (en) *	1991-05-15	1996-02-20	E. I. Du Pont De Nemours And Company	Composition of angiotensin-II receptor antagonists and calcium channel blockers
NZ242724A (en)	1991-05-15	1994-09-27	Du Pont	Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
WO1993017682A1 (fr) *	1992-03-04	1993-09-16	Abbott Laboratories	Antagonistes des recepteurs de l'angiotensine ii
US5599559A (en) *	1992-07-27	1997-02-04	Pfizer Inc.	Calcium channel blocking polypeptide from agelenopsis aperta and therapeutic methods employing it
US5264447A (en) *	1992-09-01	1993-11-23	Merck & Co., Inc.	Angiotensin II antagonist
CA2125251C (fr) *	1993-06-07	2005-04-26	Yoshiyuki Inada	Composition pharmaceutique pour le traitement des affections mediees par l'angiotensine ii
US5721263A (en) *	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
ES2154277T3 (es) *	1993-07-15	2001-04-01	Hoffmann La Roche	Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
CA2181461A1 (fr) *	1994-02-08	1995-08-17	Alica Huxley	Antagonistes de l'angiotensine ii destines au traitement du glaucome normotensif
FI963611A7 (fi) *	1994-03-17	1996-09-13	Novartis Ag	Diabeettisen munuaissairauden hoito valsartaanilla
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
ES2552639T3 (es)	1998-07-10	2015-12-01	Novartis Pharma Ag	Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos

1999
- 1999-07-09 ES ES10177093.1T patent/ES2552639T3/es not_active Expired - Lifetime
- 1999-07-09 NZ NZ527598A patent/NZ527598A/xx not_active IP Right Cessation
- 1999-07-09 PT PT101770931T patent/PT2322174E/pt unknown
- 1999-07-09 SG SG200300082-5A patent/SG142116A1/en unknown
- 1999-07-09 CN CNB998097764A patent/CN1234357C/zh not_active Expired - Lifetime
- 1999-07-09 BR BR9912021-6A patent/BR9912021A/pt not_active IP Right Cessation
- 1999-07-09 CA CA2678722A patent/CA2678722C/fr not_active Expired - Lifetime
- 1999-07-09 CA CA002336822A patent/CA2336822C/fr not_active Expired - Lifetime
- 1999-07-09 RU RU2001102585/15A patent/RU2450813C2/ru active Protection Beyond IP Right Term
- 1999-07-09 HU HU0102828A patent/HU229383B1/hu active Protection Beyond IP Right Term
- 1999-07-09 SK SK31-2001A patent/SK285863B6/sk not_active IP Right Cessation
- 1999-07-09 DK DK10177093.1T patent/DK2322174T3/en active
- 1999-07-09 DK DK99934647T patent/DK1096932T3/da active
- 1999-07-09 AU AU50349/99A patent/AU753486B2/en not_active Expired
- 1999-07-09 PL PL99345897A patent/PL194604B1/pl unknown
- 1999-07-09 TR TR2001/00062T patent/TR200100062T2/xx unknown
- 1999-07-09 SI SI9930996T patent/SI1096932T1/sl unknown
- 1999-07-09 JP JP2000558803A patent/JP2002520274A/ja active Pending
- 1999-07-09 WO PCT/EP1999/004842 patent/WO2000002543A2/fr not_active Ceased
- 1999-07-09 AT AT99934647T patent/ATE371448T1/de active
- 1999-07-09 DE DE69936992T patent/DE69936992T2/de not_active Expired - Lifetime
- 1999-07-09 EP EP99934647A patent/EP1096932B1/fr not_active Revoked
- 1999-07-09 CN CNA200510072738XA patent/CN1733307A/zh active Pending
- 1999-07-09 PT PT99934647T patent/PT1096932E/pt unknown
- 1999-07-09 KR KR10-2004-7011566A patent/KR20040078140A/ko not_active Ceased
- 1999-07-09 EP EP10177093.1A patent/EP2322174B1/fr not_active Revoked
- 1999-07-09 CZ CZ20010087A patent/CZ299429B6/cs unknown
- 1999-07-09 ES ES99934647T patent/ES2289814T3/es not_active Expired - Lifetime
- 1999-07-09 DE DE200712000055 patent/DE122007000055I1/de active Pending
- 1999-07-09 EP EP07105179A patent/EP1870098A3/fr not_active Withdrawn
- 1999-07-09 SI SI9931078T patent/SI2322174T1/sl unknown
- 1999-07-09 RU RU2001102585/15K patent/RU2243768C2/ru active
- 1999-07-09 CZ CZ2007-647A patent/CZ304359B6/cs not_active IP Right Cessation
- 1999-07-09 NZ NZ509260A patent/NZ509260A/en not_active IP Right Cessation
- 1999-07-09 KR KR1020017000323A patent/KR100550167B1/ko not_active Expired - Fee Related
- 1999-07-09 IL IL14066599A patent/IL140665A0/xx unknown
- 1999-07-09 ID IDW20010051A patent/ID27664A/id unknown
2001
- 2001-01-01 IL IL140665A patent/IL140665A/en unknown
- 2001-01-08 NO NO20010113A patent/NO331802B1/no not_active IP Right Cessation
- 2001-01-09 ZA ZA200100232A patent/ZA200100232B/en unknown
2007
- 2007-09-06 LU LU91358C patent/LU91358I2/fr unknown
- 2007-09-10 NL NL300290C patent/NL300290I2/nl unknown
- 2007-10-25 CY CY20071101384T patent/CY1107779T1/el unknown
- 2007-10-30 CY CY200700026C patent/CY2007026I2/el unknown
2011
- 2011-07-04 IL IL213926A patent/IL213926A0/en unknown
2012
- 2012-03-20 RU RU2012110522/15A patent/RU2012110522A/ru unknown
- 2012-07-03 NO NO2012013C patent/NO2012013I2/no unknown
2015
- 2015-10-06 CY CY20151100890T patent/CY1116770T1/el unknown
2016
- 2016-03-07 BE BE2016C011C patent/BE2016C011I2/nl unknown
- 2016-03-07 NL NL300800C patent/NL300800I2/nl unknown
- 2016-03-07 CY CY2016006C patent/CY2016006I2/el unknown
- 2016-03-07 LU LU92992C patent/LU92992I2/fr unknown
- 2016-03-07 FR FR16C0008C patent/FR16C0008I2/fr active Active

Also Published As

Publication number	Publication date
PL194604B1 (pl)	2007-06-29
PT1096932E (pt)	2007-09-21
HK1036758A1 (en)	2002-01-18
HK1152897A1 (en)	2012-03-16
IL213926A0 (en)	2011-07-31
HUP0102828A3 (en)	2002-11-28
ID27664A (id)	2001-04-19
NO20010113L (no)	2001-03-09
SG142116A1 (en)	2008-05-28
CZ299429B6 (cs)	2008-07-23
DE122007000055I1 (de)	2007-12-13
WO2000002543A3 (fr)	2000-06-29
ES2289814T3 (es)	2008-02-01
NL300290I2 (nl)	2008-11-03
CY2007026I1 (el)	2009-11-04
NO20010113D0 (no)	2001-01-08
CZ200187A3 (en)	2001-05-16
EP1870098A3 (fr)	2010-07-07
JP2002520274A (ja)	2002-07-09
BE2016C011I2 (fr)	2018-12-04
EP1870098A2 (fr)	2007-12-26
NZ509260A (en)	2003-09-26
CY1107779T1 (el)	2010-07-28
WO2000002543A2 (fr)	2000-01-20
HU229383B1 (en)	2013-11-28
KR20040078140A (ko)	2004-09-08
CY2016006I1 (el)	2016-10-05
HUP0102828A2 (hu)	2002-04-29
AU5034999A (en)	2000-02-01
SI2322174T1 (sl)	2015-12-31
NO2012013I2 (no)	2014-10-27
DE69936992T2 (de)	2008-03-06
PL345897A1 (en)	2002-01-14
CN1234357C (zh)	2006-01-04
RU2243768C2 (ru)	2005-01-10
CA2678722C (fr)	2013-08-27
NO2012013I1 (no)	2012-07-30
TR200100062T2 (tr)	2001-06-21
NO331802B1 (no)	2012-04-10
EP2322174B1 (fr)	2015-09-23
CZ304359B6 (cs)	2014-03-26
SK312001A3 (en)	2001-06-11
RU2012110522A (ru)	2013-09-27
RU2450813C2 (ru)	2012-05-20
SK285863B6 (sk)	2007-10-04
DK1096932T3 (da)	2007-10-15
CN1312715A (zh)	2001-09-12
ATE371448T1 (de)	2007-09-15
CY1116770T1 (el)	2016-10-05
DK2322174T3 (en)	2015-10-12
CY2016006I2 (el)	2016-10-05
CA2336822C (fr)	2009-11-17
NL300290I1 (fr)	2007-11-01
NL300800I2 (fr)	2016-07-27
EP2322174A3 (fr)	2011-07-27
IL140665A0 (en)	2002-02-10
EP1096932B1 (fr)	2007-08-29
CA2678722A1 (fr)	2000-01-20
KR20010079517A (ko)	2001-08-22
SI1096932T1 (sl)	2008-04-30
CA2336822A1 (fr)	2000-01-20
EP1096932A2 (fr)	2001-05-09
BR9912021A (pt)	2001-04-03
DE69936992D1 (de)	2007-10-11
IL140665A (en)	2012-12-31
FR16C0008I1 (fr)	2016-04-15
NZ527598A (en)	2005-04-29
LU92992I2 (fr)	2016-05-09
AU753486B2 (en)	2002-10-17
EP2322174A2 (fr)	2011-05-18
KR100550167B1 (ko)	2006-02-08
PT2322174E (pt)	2015-10-27
FR16C0008I2 (fr)	2018-06-08
ES2552639T3 (es)	2015-12-01
CY2007026I2 (el)	2009-11-04
CN1733307A (zh)	2006-02-15
ZA200100232B (en)	2002-04-09